Association of Expression of YTH‐Domain Family Protein 3 (YTHDF3) With Brain Metastases and Unfavorable Survival in Patients With Stage IV Lung Adenocarcinoma
Molecular Carcinogenesis · 2026-09 · 65 (9) · 1043-1051
DOI: 10.1002/mc.70140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 16.06.2026. Verfasst von Zhen Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Brain Neoplasms, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background YTH‐domain family protein 3 (YTHDF3) is an N 6 ‐methyladenosine (m6A) reader that plays important roles in regulating mRNA stability and translation. It can promote tumor proliferation, migration, and invasion; however, little is known about the associations between YTHDF3 expression and brain metastasis (BM) and prognosis in the advanced lung adenocarcinoma (LUAD). Immunohistochemistry (IHC) was performed for YTHDF3 expression in LUAD specimens. The correlations were evaluated between YTHDF3 expression and clinicopathological features. Furthermore, the Kaplan‐Meier analysis and Cox proportional hazard model were used to assess effect of YTHDF3 on patient clinical outcomes. There is a strong correlation between YTHDF3 expression and BM in LUAD (r = 0.656, p < 0.001), and the expression of YTHDF3 was significantly higher in patients with BM than in those without BM (66.7% vs . 14.5%, p < 0.001). Moreover, the patients with high YTHDF3 expression had an approximately 12‐fold increased risk to have BM compared with those with low YTHDF3 expression (aOR,12.2; 95% CI, 2.4–18.1). Furthermore, the patients with high YTHDF3 expression had worse progression‐free survival (PFS) and overall survival (OS) in all patients with stage IV LUAD and those with BM (all log‐rank p < 0.001). Multivariable analyzes showed that patients with higher YTHDF3 expression was significantly associated with both worse PFS and OS in all patients with stage IV LUAD (aHR, 2.7, 95% CI, 1.2‐5.9 for PFS and aHR, 3.0, 95%CI, 1.8–5.3 for OS) and those with BM (aHR, 2.9, 95%CI, 1.7–4.8 for PFS and aHR, 3.3, 95%CI, 1.6–5.7 for OS). Overexpression of YTHDF3 was significantly associated with BM and poor survival outcomes among patients with LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
- Delartment of Medical Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
- Department of General Surgery, Anqiu Maternal and Child Health Hospital, Weifang, China.
- Department of Otorhinolaryngology, Qilu Hospital of Shandong University, Jinan, China.
- NHC Key Laboratory of Otorhinolaryngology (Shandong University), Jinan, China.
- Department of Otorhinolaryngology Head and Neck Surgery, Qilu Hospital of Shandong University, Qingdao, China.
Zitieren
APA
Wang, Z., Qiu, X., Liu, P., Li, Y., Wang, Y., Lin, Y., Shao, P., & Zhou, F. (2026). Association of Expression of YTH‐Domain Family Protein 3 (YTHDF3) With Brain Metastases and Unfavorable Survival in Patients With Stage IV Lung Adenocarcinoma. Molecular Carcinogenesis, 65(9), 1043-1051. https://doi.org/10.1002/mc.70140
Vancouver
Wang Z, Qiu X, Liu P, Li Y, Wang Y, Lin Y, et al. Association of Expression of YTH‐Domain Family Protein 3 (YTHDF3) With Brain Metastases and Unfavorable Survival in Patients With Stage IV Lung Adenocarcinoma. Molecular Carcinogenesis. 2026;65(9):1043-1051. doi:10.1002/mc.70140
BibTeX
@article{Wang2026,
author = {Wang, Zhen and Qiu, Xiaowen and Liu, Peiji and Li, Yinguang and Wang, Yin and Lin, Yun and Shao, Peng and Zhou, Fang},
title = {Association of Expression of YTH‐Domain Family Protein 3 (YTHDF3) With Brain Metastases and Unfavorable Survival in Patients With Stage IV Lung Adenocarcinoma},
journal = {Molecular Carcinogenesis},
year = {2026},
volume = {65},
number = {9},
pages = {1043--1051},
doi = {10.1002/mc.70140}
}
EUVIMED